Krystal Biotech, Inc.
KRYSNASDAQHealthcare● Active
$301.76
+$0.76(+0.25%)
Market Cap$8.9B
P/E Ratio—
52W High$319.48
52W Low$127.99
Krystal Biotech, Inc. (KRYS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KRYS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
$1.83
Est. $1.45 · +26.2%
Revenue
$0.12B
Est. $0.11B · +3.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
KRYS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $1.81 | — | — | — | $0.12B | — |
| ▲ Q2 FY2026 | May 4, 2026 | $1.45 | $1.83 | +26.2% | $0.12B | $0.11B | +3.8% |
| ▲ Q1 FY2026 | Feb 17, 2026 | $1.62 | $1.70 | +4.9% | $0.11B | $0.11B | +1.7% |
| ▲ Q4 FY2025 | Nov 3, 2025 | $1.12 | $2.66 | +137.5% | $0.10B | $0.11B | -7.1% |
| ▲ Q3 FY2025 | Aug 4, 2025 | $1.08 | $1.29 | +19.4% | $0.10B | $0.10B | +0.7% |
| ▼ Q2 FY2025 | May 6, 2025 | $1.38 | $1.20 | -13.0% | $0.09B | $0.11B | -16.8% |
| ▲ Q1 FY2025 | Feb 19, 2025 | $1.29 | $1.52 | +17.8% | $0.09B | $0.09B | -0.2% |
| ▲ Q4 FY2024 | Nov 4, 2024 | $0.90 | $0.91 | +1.1% | $0.08B | $0.09B | -8.2% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$1.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
$1.83
EPS Est.
$1.45
EPS Surpr.
+26.2%
Revenue
$0.12B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
$1.70
EPS Est.
$1.62
EPS Surpr.
+4.9%
Revenue
$0.11B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$2.66
EPS Est.
$1.12
EPS Surpr.
+137.5%
Revenue
$0.10B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$1.29
EPS Est.
$1.08
EPS Surpr.
+19.4%
Revenue
$0.10B
Q2 FY2025
May 6, 2025Miss
EPS Actual
$1.20
EPS Est.
$1.38
EPS Surpr.
-13.0%
Revenue
$0.09B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
$1.52
EPS Est.
$1.29
EPS Surpr.
+17.8%
Revenue
$0.09B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.91
EPS Est.
$0.90
EPS Surpr.
+1.1%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $3.43 | $3.65 | $3.96 | 2 |
| Q3 FY2027 | $2.78 | $2.96 | $3.21 | 2 |
| Q2 FY2027 | $2.34 | $2.49 | $2.70 | 2 |
| Q1 FY2027 | $2.56 | $2.72 | $2.95 | 2 |
| Q4 FY2026 | $2.04 | $2.17 | $2.36 | 4 |
| Q3 FY2026 | $1.64 | $1.99 | $2.33 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.2B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.2B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +26.2% | $266.04 | $286.95 | +7.86% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +4.9% | $276.45 | $287.84 | +4.12% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +137.5% | $197.51 | $197.85 | +0.17% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +19.4% | $156.98 | $134.94 | -14.04% |
| ▼ Q2 FY2025 | May 6, 2025 | -13.0% | $162.29 | $139.47 | -14.06% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +17.8% | $156.69 | $176.17 | +12.43% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +1.1% | $176.39 | $170.85 | -3.14% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +72.0% | $191.94 | $180.71 | -5.85% |
Q2 FY2026+7.86%
Report Date
May 4, 2026
EPS Beat/Miss
+26.2%
Price Before
$266.04
Price After
$286.95
Q1 FY2026+4.12%
Report Date
Feb 17, 2026
EPS Beat/Miss
+4.9%
Price Before
$276.45
Price After
$287.84
Q4 FY2025+0.17%
Report Date
Nov 3, 2025
EPS Beat/Miss
+137.5%
Price Before
$197.51
Price After
$197.85
Q3 FY2025-14.04%
Report Date
Aug 4, 2025
EPS Beat/Miss
+19.4%
Price Before
$156.98
Price After
$134.94
Q2 FY2025-14.06%
Report Date
May 6, 2025
EPS Beat/Miss
-13.0%
Price Before
$162.29
Price After
$139.47
Q1 FY2025+12.43%
Report Date
Feb 19, 2025
EPS Beat/Miss
+17.8%
Price Before
$156.69
Price After
$176.17
Q4 FY2024-3.14%
Report Date
Nov 4, 2024
EPS Beat/Miss
+1.1%
Price Before
$176.39
Price After
$170.85
Q3 FY2024-5.85%
Report Date
Aug 5, 2024
EPS Beat/Miss
+72.0%
Price Before
$191.94
Price After
$180.71
Avg Beat Reaction+0.22%
Avg Miss Reaction-14.06%
Beat Rate7 / 8 quarters
Largest Move-14.06% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KRYS ends December
Krystal Biotech, Inc. (KRYS) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $1.83 — beating the analyst consensus of $1.45 by +26.2%. KRYS has beaten EPS estimates for 4 consecutive quarters. The next KRYS earnings date is expected around September 1, 2026.
Each quarter, investors track KRYS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KRYS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KRYS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KRYS earnings · 5 questionsKrystal Biotech, Inc.'s next earnings report is expected around September 1, 2026. KRYS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KRYS historically reports after market close (AMC).
KRYS earnings datewhen is KRYS earningsKRYS next earnings datewhen does KRYS report earningsKRYS earnings calendar
▸ Source: FMP · Krystal Biotech, Inc. SEC filings · US GAAP · Krystal Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026